# ADHD

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/adhd
Canonical HTML page: https://getbiobrief.com/entity/adhd

## Recent coverage (1 stories)

### GLP-1 Agonists in ADHD: Emerging Research into Neuropsychiatric Applications
2026-03-10 08:09:10 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Researchers are investigating whether GLP-1 receptor agonists like semaglutide could mitigate symptoms of ADHD by modulating dopamine pathways in the brain. While primarily used for diabetes and obesity, anecdotal evidence and early-stage studies suggest a potential role for these blockbuster drugs in treating executive dysfunction and impulsivity.
Full story: https://getbiobrief.com/story/glp1-adhd-symptoms-research-ozempic

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.